Synapse - Works

Results (988)

Continuous treatment with lenalidomide plus low-dose dexamethasone (Ld) versus Ld induction followed by autologous stem cell transplant (ASCT) in patients with newly diagnosed multiple myeloma (NDMM): A pooled analysis of two randomized clinical trials

Meeting Abstract

Lentzsch, S.; Villanueva, N.; Nguyen, J.; Landau, H.; Lendvai, N.; Miao, S.; Schecter, J. M.; Reyna, M.; Mapara, M. Y.; Redner, R. L.; more...
Blood (2015)

Fulltext@MSK | Save

No risk of arterial or venous thrombosis in monoclonal gammopathy of undetermined significance: Results from a population-based study

Meeting Abstract

Lindqvist, E. K.; Lund, S. H.; Costello, R.; Burton, D.; Korde, N. S.; Mailankody, S.; Gudnason, V.; Eiriksdottir, G.; Launer, L.; Harris, T. B.; more...
Blood (2015)

Fulltext@MSK | Save

Biomarkers of cardiotoxicity among multiple myeloma patients subsequently treated with proteasome inhibitor therapy

Meeting Abstract

Lendvai, N.; Devlin, S.; Patel, M.; Knapp, K. M.; Ekman, D.; Grundberg, I.; Chung, D. J.; Hassoun, H.; Koehne, G.; Lesokhin, A. M.; more...
Blood (2015)

Fulltext@MSK | Save

Induction with bortezomib and dexamethasone (BD) followed by risk adapted high dose melphalan and autologous stem cell transplantation and BD consolidation in patients with AL amyloidosis: A phase II feasibility study

Meeting Abstract

Landau, H.; Montanez, N.; Cowan, A.; Hoover, E.; Flombaum, C.; Liu, J.; Maurer, M.; Lendvai, N.; Landgren, O.; Giralt, S. A.; more...
Blood (2015)

Fulltext@MSK | Save

Incidence and management of proteasome inhibitor-related cardiotoxicity in multiple myeloma patients at Memorial Sloan Kettering Cancer Center

Meeting Abstract

Land, J.; Afifi, S.; Adel, N. G.; Devlin, S.; Arora, A.; Lendvai, N.; Landgren, O.
Blood (2015)

Fulltext@MSK | Save

The long PD-1 receptor binding kinetics of nivolumab may increase efficacy of subsequent therapy in relapsed and refractory multiple myeloma patients

Meeting Abstract

Funt, S. A.; Page, D. B.; Cattry, D.; Lendvai, N.; Hassoun, H.; Landgren, O.; Borrello, I. M.; Lesokhin, A. M.
Blood (2015)

Fulltext@MSK | Save

T cell exhaustion/senescence in relapsed multiple myeloma after autologous stem cell transplantation

Meeting Abstract

Chung, D. J.; Pronschinske, K. B.; Shyer, J. A.; Sharma, S.; Leung, S.; Curran, S. A.; Lesokhin, A. M.; Devlin, S.; Giralt, S. A.; Young, J. W.
Blood (2015)

Fulltext@MSK | Save

Phase 2 study of carfilzomib (CFZ) with or without filanesib (FIL) in patients with advanced multiple myeloma (MM)

Meeting Abstract

Zonder, J. A.; Usmani, S.; Scott, E. C.; Hofmeister, C. C.; Lendvai, N.; Berdeja, J. C.; Anderson, L. D.; Hari, P.; Singhal, S.; Orloff, G.; more...
Blood (2015)

Fulltext@MSK | Save

Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor based therapy: Phase I results

Meeting Abstract

Voorhees, P. M.; Mulkey, F.; Hassoun, H.; Paba-Prada, C. E.; Efebera, Y. A.; Hoke, E.; Aquino, G.; Carlisle, D.; Suman, V.; Richardson, P. G.
Blood (2015)

Fulltext@MSK | Save

A dose finding phase II trial of isatuximab (SAR650984, anti-CD38 mAb) as a single agent in relapsed/refractory multiple myeloma

Meeting Abstract

Martin, T.; Richter, J.; Vij, R.; Cole, C.; Atanackovic, D.; Zonder, J.; Kaufman, J. L.; Bensinger, W.; Dimopoulos, M. A.; San Miguel, J.; more...
Blood (2015)

Fulltext@MSK | Save